Dear Navigators, Oncology navigation has made great strides in improving cancer care, including access to quality care, for nearly 3 decades. Navigation programs are well established for most patient populations [ Read More ]
Best Practices in Hematologic Malignancies – December 2017 Vol 8
Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma
Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a proteasome inhibitor, was approved by the FDA on June 16, 2017.
“This offers another alternative to patients with multiple myeloma who haven’t seen lasting effects from other types of treatment,” said Jan van de Winkel, PhD, Chief Executive Officer, Genmab.
The approval was based on data from the phase 1 EQUULEUS clinical trial involving 103 patients with multiple myeloma who had received previous therapy. Patients received 16 mg/kg of daratumumab plus pomalidomide and dexamethasone until disease progression. The primary efficacy end point was the overall response rate (ORR).
The ORR was 59.2%. The stringent complete response rate was 7.8%, the complete response rate was 5.8%, the very good partial response rate was 28.2%, and the partial response rate was 17.5%. The most common (≥20%) all-grade adverse reactions in patients who received daratumumab plus pomalidomide and dexamethasone included infusion reactions, diarrhea, constipation, nausea, vomiting, fatigue, pyrexia, upper respiratory tract infection, muscle spasms, back pain, arthralgia, dizziness, insomnia, cough, and dyspnea. Overall, 49% of patients had serious adverse reactions, and 13% of patients discontinued therapy because of adverse reactions.
With 5-year survival rates for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) at 86% and 71%, respectively, the number of lymphoma survivors is on the rise, but achieving long-term quality [ Read More ]